Cancer United Kingdom, Europe

NHS patients with advanced anal cancer get their first targeted treatment

The immunotherapy retifanlimab was approved by the UK medicines regulator, recommended by NICE and made available in England within a week. In a major trial, people given it with chemotherapy lived a median of 32.8 months, compared with 22.2 months on chemotherapy alone.

By The GGND Team 4 min read

An intravenous drip bag hangs from a stand beside an empty reclining chair in a calm, bright NHS chemotherapy day unit, with a window and green plants in the background.
AI-generated illustration; not a photograph of the reported event. An illustrative view of a hospital day unit where infusions are given.

What happened

People in England with anal cancer that has spread, or come back and cannot be removed by surgery, can now be offered a new immunotherapy on the NHS. On 12 November 2026, NICE recommended retifanlimab, sold as Zynyz and made by Incyte Biosciences, for use with platinum-based chemotherapy in adults with this form of the disease. It is the first time NICE has recommended a drug for this specific cancer, and about 250 people in England could benefit.

The decision came together with regulatory approval. The Medicines and Healthcare products Regulatory Agency (MHRA) said it had approved retifanlimab, with carboplatin and paclitaxel, for adults with squamous cell carcinoma of the anal canal that cannot be removed by surgery and is metastatic or has come back in the same area. The approval was granted on 5 November and announced on 11 November. NHS England said the drug was approved, recommended and made available to patients within a week, through its Cancer Drugs Fund.

Why it matters

Anal cancer is rare, and when it has spread the outlook is poor. NICE said there were an estimated 1,600 new diagnoses a year in the UK between 2017 and 2019, two-thirds of them in women. Only around 20 per cent of people whose cancer has spread live for five years, compared with around 90 per cent when it has not spread. Until now, the usual treatment for advanced disease has been chemotherapy alone.

Retifanlimab works by blocking a protein called PD-1 on immune cells, “releasing the brakes” so the immune system can recognise and attack cancer cells, NICE explained. In the trial behind the approval, named POD1UM-303 by pharmaphorum, people given retifanlimab with chemotherapy lived a median of 32.8 months, compared with 22.2 months for those given chemotherapy and a placebo. The time before the cancer got worse was 9.3 months, against 7.4 months, according to NICE. NHS England described the gain as patients living on average 11 months longer.

Helen Knight, director of medicines evaluation at NICE, said: “Anal cancer is a devastating disease with limited treatments so I’m pleased we can recommend this effective, life-extending drug that offers renewed hope to hundreds of people.”

Access to this life-extending drug is one of the most significant steps in decades for people living with advanced anal cancer.

Professor Peter Johnson, national clinical director for cancer at NHS England

The wider picture

The speed is part of the story. NICE published its final draft guidance at the same time as the MHRA approval, and said it is now publishing guidance on medicines 30 per cent faster than before April 2024. Pharmaphorum described this as another example of the two bodies assessing new medicines in parallel. It reported that the drug will be available through the Cancer Drugs Fund straight away, with routine commissioning to start within 90 days.

Patient groups welcomed the decision. David Winterflood, chief executive of the Anal Cancer Foundation, said: “For a cancer that has been overlooked for too long, this advance brings much-needed attention and hope for continued progress.” Dr Claire Coughlan of Bowel Cancer UK said the decision “could offer patients precious extra time with their loved ones”.

Prevention matters too. NICE said human papillomavirus (HPV) infection is linked to about 90 per cent of UK cases, and HIV infection is another key risk factor. Patient experts told NICE’s committee that low awareness of symptoms, which can include bleeding, pain or itching and changes in bowel habit, means the disease is often found late. In GGND’s view, the new drug helps people once cancer has spread, but HPV vaccination and earlier diagnosis will do more to cut deaths over time.

Could it work elsewhere?

Retifanlimab has also been approved in the European Union, pharmaphorum has reported, so other European health systems can follow. In GGND’s view, the more transferable lesson is the process: a regulator and a cost-effectiveness body working side by side, so patients do not wait months between “approved” and “available”.

What remains unresolved

  • Price. The NHS gets a confidential discount, so the public cannot see what the drug costs or judge its value for money directly. NICE applied a 1.2 severity modifier, which raises the threshold at which a drug counts as cost-effective.
  • Final draft. NICE’s guidance is final draft; the routine-commissioning arrangements still have to follow within 90 days.
  • Not a cure. The trial gains are median figures. Some patients respond for much longer, others less, and immunotherapy can cause side effects.
  • Beyond England. NICE covers England, and pharmaphorum also mentions Wales. Access in Scotland and Northern Ireland depends on their own decisions.

What happens next

Hospitals in England can begin offering retifanlimab now. It is given as a drip once every four weeks for up to a year, at first alongside chemotherapy, NHS England said. GGND will watch for routine commissioning and for decisions elsewhere in the UK.

Sources

  1. NICE Hundreds of people set to benefit after green light for life-extending advanced anal cancer treatment (12 November 2026)
  2. MHRA (GOV.UK) MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer (11 November 2026)
  3. NHS England NHS fast tracks rollout of first ever targeted treatment for anal cancer (12 November 2026)
  4. pharmaphorum NHS use of Incyte’s anal cancer drug Zynyz backed by NICE (12 November 2026)

Analysis and context are by The GGND Team. Where we draw our own conclusions, we say so. To report an error, contact us.

Keep good news free

Support GGND

GGND Magazine and GGND Daily are free to read, with no account and no paywall. A donation helps us find, check and tell more good news from every continent.

Donate to GGND